HonCode

Go Back   HER2 Support Group Forums > Inflammatory Breast Cancer
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 02-21-2009, 10:02 AM   #1
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,778
new article on prognostic importance (or lack of it) of her2 +ivity on IBC

Breast Cancer Res. 2009 Feb 19;11(1):R9. [Epub ahead of print]

Prognostic impact of HER2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2014 IBC patient cases from the California Cancer Registry.

Zell JA, Tsang WY, Taylor TH, Mehta RS, Anton-Culver H.
ABSTRACT: INTRODUCTION: Inflammatory breast cancer (IBC) is an aggressive form of breast cancer associated with over-expression of Her-2-Neu (HER2) and poor survival. We investigated survival differences for IBC patient cases based on hormone and HER2 receptor status using data from the California Cancer Registry (CCR), as contrasted with locally-advanced breast cancer (LABC), metastatic breast cancer (MBC) and non-T4 breast cancer. METHODS: A case-only analysis of 80,099 incident female breast cancer patient cases in CCR during 1999 - 2003 was performed, with follow-up through March 2007. Overall survival (OS) and breast cancer-specific survival (BC-SS) was analyzed using Kaplan-Meier methods and Cox proportional hazards ratios (HR). RESULTS: 2014 IBC, 1268 LABC, 3059 MBC, and 73,758 non-T4 breast cancer patient cases were identified. HER2+ was associated with advanced tumor stage (P <0.0001). IBC patient cases were more likely to be HER2+ (40%) and less likely to be hormone receptor positive (HmR+) (59%) compared to LABC (35%, 69%), MBC (35%, 74%), and non-T4 patient cases (22%, 82%). HmR+ status was associated with improved OS and BC-SS for each breast cancer subtype after adjustment for clinically relevant factors. In multivariate analysis, HER2+ (versus HER2-) status was associated with poor BC-SS for non-T4 patient cases (HR = 1.16, 95% confidence interval (CI) 1.05 - 1.28) and had a borderline significant association with improved BC-SS for IBC (HR = 0.82, 95% CI 0.68 - 0.99). CONCLUSIONS: Despite an association with advanced tumor stage, HER2+ status is not an independent adverse prognostic factor for survival among IBC patient cases.
PMID: 19228416
Lani is offline   Reply With Quote
Old 02-21-2009, 04:25 PM   #2
vickie h
Senior Member
 
vickie h's Avatar
 
Join Date: Jun 2006
Location: san luis obispo, ca
Posts: 1,150
Thank You, Lani. Info I didn't know before today as far as Her2+ and Ibc. Love, Vickie
__________________
Love and Hugs, Vickie

Life's not about waiting for the storm to pass,
It's about learning to dance in the rain.


Feb 04 IBC IIIC/IV er-/pr- her2+++
3/04 TCH X4
7/ 04 MRM 9/04 Taxol/herceptin wkly 1 yr 33X rads
11/04 skin mets 33x rads,10/05 Avast/Herc. 11 mos.
8/ 06 PET mets lymphs, neck
9/ 06 Navelbine/herceptin
11/ 06 PET NED
2/ 07 skin mets, 4/07 Xeloda, 5/07 add Tykerb
2/ 08 Tykerb failed. Doxil /Herceptin 6 months
8/08 PET skin mets, 8/08 Abraxane/Avastin
11/ 08 PET prog., skin mets
1/09 PET/CT progress, 1/09 Ixempra, 2/09 add Xeloda and low dose Naltrexone
2/09 off Ixempra/Xeloda
3/09 navelbine/herc/cytoxin 4/09 PET shows regress.7/09 start Topotecan. Failed.
8/09 extensive mets rgt brst, back and torso. starting Pazopanib clinical trial.
vickie h is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 06:28 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter